36. Reck M, Rodríguez -Abreu, Robinson AG,et al. Pembrolizumab versus Chemotherap y for PD -L1–Positive Non–Small -Cell L ung. Cancer. NEJM. 2016; DOI : 10.1056/NEJMoa1606774 37. Quoix E, Lena H, Losonczy G et al. TG4010 immunotherapy and first -line chemotherap y for advanced non -small -cell lung cancer (TIME): r esults from the ph ase 2b part of a ramdomised, double -blind, placebo -controlled, phase 2b/3 trial. L ancet Oncol, 2016.